Corporate Profile KalVista is a pharmaceutical company focused on the discovery, development and commercialization of small molecule protease inhibitors as new treatments for diseases with significant unmet needs. Minimum 15 minutes delayed. Source: LSEG View All Stock Information All Stock Information
KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 2026 Global Angioedema Leadership Conference Mar 20, 2026
KalVista Pharmaceuticals to Report Eight Months Fiscal Year 2025 Financial Results and Provide Corporate Update on March 25, 2026 Mar 18, 2026
